MISSION AND VISION
Our mission and vision are to revolutionize drug discovery and development of heart therapeutics with our suite of proprietary bioengineered human heart constructs, and to further develop them into transplantable grafts for cell-based regenerative heart therapies with superior safety and efficacy.
Make A Heart, Save A Heart
Founded in 2014, Novoheart has the longest history in commercializing human cardiac tissue engineering for disease modeling and drug screening. Our founders were among the first-generation biomedical engineers who started the fields back in the late 90s. Novoheart has the industry’s most sophisticated and comprehensive human cardiac tissue engineering platform and the only Human-Heart-in-a-Jar.
Novoheart was previously dually publicly-listed on the Toronto Stock Exchange and Frankfurt Stock Exchange before its acquisition and privatisation by the Medera group in 2020. The merger allows Novoheart as a Medera portfolio company to have access to highly specialised expertise in clinical trials from IND applications to patient enrolment as well as advanced cGMP manufacturing of gene and cell products for patients, providing a one-stop platform for Novoheart as well as its clients and partners.
